AMD - BOTTOM AT $36.75 / MARKET BOTTOM / OPEX / LONG UPDATE
1. AMD touched a low on March 18, 2020;
2. This price was $36.75;
3. We published buy trades for AMD, NVDA, ADBE, CRM, MSFT, MU, and many other of our favourite names, with nice average down entry points on various dates;
2. This price was $36.75;
3. We published buy trades for AMD, NVDA, ADBE, CRM, MSFT, MU, and many other of our favourite names, with nice average down entry points on various dates;
Comment:
6. As I commented to one of Canada's Top Traders yesterday, and over the past few weeks, we believe that options expiration on March 20, 2020, "may" mark the bottom of this crash / correction;
7. Nothing is completely certain, but probability suggests a 90 percent chance of a bottom on March 18, with our FINAL buy recommendations listed as BACK UP THE TRUCK ideas. We apologize for our GLD call at this point, but we firmly believe GLD will track back up nicely with the Market as we recover;
VIRUS TREATMENT UPDATES
7. Nothing is completely certain, but probability suggests a 90 percent chance of a bottom on March 18, with our FINAL buy recommendations listed as BACK UP THE TRUCK ideas. We apologize for our GLD call at this point, but we firmly believe GLD will track back up nicely with the Market as we recover;
VIRUS TREATMENT UPDATES
Comment:
This will be a running thread for the next few hours on the state of this Market, Bill Ackman (HELL IS COMING), AMD Max Pain at $37.75, and a recap of our buy / trade points during this crash.
Comment:
Just for the record, we predicted FUTURES LIMIT UP, when the futures were DOWN at 7pm EST last night. We have a transcript of that call, and WE WERE WELL POSITIONED FOR THIS, barring some unforeseen BLACK SWAN this morning, which could only be Global Thermonuclear War at this point.
Comment:
VIRUS TREATMENTS
March 19, 2020
FDA News Release
Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments
www.fda.gov/news-eve...velopment-treatments
March 19, 2020
FDA News Release
Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments
www.fda.gov/news-eve...velopment-treatments
Comment:
The U.S. Food and Drug Administration continues to play a critical role in the multifaceted all-of-government response to the COVID-19 pandemic, which includes, among other things, facilitating medical countermeasures to treat and prevent the disease, and surveilling the medical product and food supply chains for potential shortages or disruptions and helping to mitigate such impacts, as necessary.
Comment:
Coronavirus updates: Trump pushes FDA to fast-track virus treatments
March 20, 12:46AM EST
President Trump says he is ordering the FDA to fast-track the use of two drugs for sick patients, though the agency says it could still take months of clinical trials. More than 14,200 people have now tested positive in the U.S. and at least 187 have died. Experts warn those numbers will continue to spike as more people are tested.
Meanwhile, Senate Republicans introduced emergency legislation to address the economic fallout from the outbreak. The third phase of the legislative response to the pandemic includes direct cash payments to many Americans. In California, Mayor Gavin Newsom announced a statewide order for residents to stay at home. The order will begin Thursday night.
The State Department told citizens who traveled abroad they should come home immediately or prepare to remain overseas. Italy now has the most coronavirus-related deaths, overtaking China, where the global outbreak started. A total of 3,405 people have died in Italy, and more than 3,100 in China, according to Johns Hopkins University.
Top questions about coronavirus - answered
Tips for managing anxiety as the pandemic spreads in the U.S.
Officials warn U.S. hospitals are unprepared for the scale of the crisis
www.cbsnews.com/live...est-news-2020-03-19/
March 20, 12:46AM EST
President Trump says he is ordering the FDA to fast-track the use of two drugs for sick patients, though the agency says it could still take months of clinical trials. More than 14,200 people have now tested positive in the U.S. and at least 187 have died. Experts warn those numbers will continue to spike as more people are tested.
Meanwhile, Senate Republicans introduced emergency legislation to address the economic fallout from the outbreak. The third phase of the legislative response to the pandemic includes direct cash payments to many Americans. In California, Mayor Gavin Newsom announced a statewide order for residents to stay at home. The order will begin Thursday night.
The State Department told citizens who traveled abroad they should come home immediately or prepare to remain overseas. Italy now has the most coronavirus-related deaths, overtaking China, where the global outbreak started. A total of 3,405 people have died in Italy, and more than 3,100 in China, according to Johns Hopkins University.
Top questions about coronavirus - answered
Tips for managing anxiety as the pandemic spreads in the U.S.
Officials warn U.S. hospitals are unprepared for the scale of the crisis
www.cbsnews.com/live...est-news-2020-03-19/
Comment:
CHLOROQUINE
Chloroquine to be tested as coronavirus treatment in the US
The President of the United States, Donald Trump, announced on 19 March that chloroquine (hydroxychloroquine/Plaquenil), a drug used to treat malaria and arthritis, were approved by the US Food and Drug Administration (FDA) to be tested as treatment for COVID-19. The drug is being tested in various clinical trials conducted by government agencies and academic institutions.
Other antivirals drugs are also planned to be fast tracked for testing for coronavirus.
Chloroquine to be tested as coronavirus treatment in the US
The President of the United States, Donald Trump, announced on 19 March that chloroquine (hydroxychloroquine/Plaquenil), a drug used to treat malaria and arthritis, were approved by the US Food and Drug Administration (FDA) to be tested as treatment for COVID-19. The drug is being tested in various clinical trials conducted by government agencies and academic institutions.
Other antivirals drugs are also planned to be fast tracked for testing for coronavirus.
Comment:
8. Chloroquine
Elon Musk has ta
Chloroquine May Fight Covid-19—and Silicon Valley’s Into It
www.wired.com/story/...con-valleys-into-it/
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
We have recently reported that two drugs, remdesivir (GS-5734) and chloroquine (CQ) phosphate, efficiently inhibited SARS-CoV-2 infection in vitro1. Remdesivir is a nucleoside analog prodrug developed by Gilead Sciences (USA). A recent case report showed that treatment with remdesivir improved the clinical condition of the first patient infected by SARS-CoV-2 in the United States2, and a phase III clinical trial of remdesivir against SARS-CoV-2 was launched in Wuhan on February 4, 2020. However, as an experimental drug, remdesivir is not expected to be largely available for treating a very large number of patients in a timely manner. Therefore, of the two potential drugs, CQ appears to be the drug of choice for large-scale use due to its availability, proven safety record, and a relatively low cost. In light of the preliminary clinical data, CQ has been added to the list of trial drugs in the Guidelines for the Diagnosis and Treatment of COVID-19 (sixth edition) published by National Health Commission of the People’s Republic of China.
www.nature.com/artic...es/s41421-020-0156-0
Elon Musk has ta
Chloroquine May Fight Covid-19—and Silicon Valley’s Into It
www.wired.com/story/...con-valleys-into-it/
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
We have recently reported that two drugs, remdesivir (GS-5734) and chloroquine (CQ) phosphate, efficiently inhibited SARS-CoV-2 infection in vitro1. Remdesivir is a nucleoside analog prodrug developed by Gilead Sciences (USA). A recent case report showed that treatment with remdesivir improved the clinical condition of the first patient infected by SARS-CoV-2 in the United States2, and a phase III clinical trial of remdesivir against SARS-CoV-2 was launched in Wuhan on February 4, 2020. However, as an experimental drug, remdesivir is not expected to be largely available for treating a very large number of patients in a timely manner. Therefore, of the two potential drugs, CQ appears to be the drug of choice for large-scale use due to its availability, proven safety record, and a relatively low cost. In light of the preliminary clinical data, CQ has been added to the list of trial drugs in the Guidelines for the Diagnosis and Treatment of COVID-19 (sixth edition) published by National Health Commission of the People’s Republic of China.
www.nature.com/artic...es/s41421-020-0156-0
Comment:
Comment:
AN UPDATED GUIDE TO THE CORONAVIRUS DRUGS AND VACCINES IN DEVELOPMENT
www.statnews.com/202...ines-in-development/
www.statnews.com/202...ines-in-development/
Comment:
Gilead Sciences
Approach: Treatment
Stage: Phase 3
Gilead’s remdesivir is being studied in five clinical trials around the world. In China, Gilead is recruiting about 1,000 patients diagnosed with the coronavirus to determine whether multiple doses of remdesivir can reverse the infection. The primary goals are reducing fever and helping patients get out of the hospital within two weeks. The drug, which previously failed in a study on Ebola virus, is administered intravenously.
www.statnews.com/202...against-coronavirus/
Approach: Treatment
Stage: Phase 3
Gilead’s remdesivir is being studied in five clinical trials around the world. In China, Gilead is recruiting about 1,000 patients diagnosed with the coronavirus to determine whether multiple doses of remdesivir can reverse the infection. The primary goals are reducing fever and helping patients get out of the hospital within two weeks. The drug, which previously failed in a study on Ebola virus, is administered intravenously.
www.statnews.com/202...against-coronavirus/
Comment:
Ascletis Pharma
Approach: Treatment
Stage: Phase 1
Chinese drug maker Ascletis Pharma is testing a combination of antivirals, one approved for HIV and one approved for hepatitis C, that might treat coronavirus infection. Last month, the company enrolled 11 patients with coronavirus-caused pneumonia and administered a cocktail of danoprevir and ritonavir. All 11 were eventually discharged, according to Ascletis. The company hasn’t disclosed plans for a larger study.
Approach: Treatment
Stage: Phase 1
Chinese drug maker Ascletis Pharma is testing a combination of antivirals, one approved for HIV and one approved for hepatitis C, that might treat coronavirus infection. Last month, the company enrolled 11 patients with coronavirus-caused pneumonia and administered a cocktail of danoprevir and ritonavir. All 11 were eventually discharged, according to Ascletis. The company hasn’t disclosed plans for a larger study.
Comment:
Moderna Therapeutics
Approach: Vaccine
Stage: Phase 1
Moderna set a drug industry record with mRNA-1273, a vaccine candidate identified just 42 days after the novel coronavirus was sequenced. The company is working with the National Institutes of Health on a healthy-volunteer study that began earlier this month. If mRNA-1273 proves itself to be safe, Moderna will enroll hundreds more patients to determine whether the vaccine protects against infection. Moderna’s product is a synthetic strand of messenger RNA, or mRNA, designed to convince bodily cells to produce antibodies against the virus. The company, founded in 2010, is yet to win Food and Drug Administration approval for any of its mRNA medicines.
www.statnews.com/202...sual-animal-testing/
Approach: Vaccine
Stage: Phase 1
Moderna set a drug industry record with mRNA-1273, a vaccine candidate identified just 42 days after the novel coronavirus was sequenced. The company is working with the National Institutes of Health on a healthy-volunteer study that began earlier this month. If mRNA-1273 proves itself to be safe, Moderna will enroll hundreds more patients to determine whether the vaccine protects against infection. Moderna’s product is a synthetic strand of messenger RNA, or mRNA, designed to convince bodily cells to produce antibodies against the virus. The company, founded in 2010, is yet to win Food and Drug Administration approval for any of its mRNA medicines.
www.statnews.com/202...sual-animal-testing/
Comment:
CanSino Biologics
Approach: Vaccine
Stage: Phase 1
CanSino Biologics, headquartered in Tianjin, is close to testing its novel coronavirus vaccine in a clinical trial in China. CanSino’s approach involves taking a snippet of coronavirus’ genetic code and entwining it with a harmless virus, thereby exposing healthy volunteers to the novel infection and spurring the production of antibodies. The company said this week that Chinese authorities approved its planned trial, which will begin as soon as possible. CanSino markets a vaccine for Ebola virus in China.
Approach: Vaccine
Stage: Phase 1
CanSino Biologics, headquartered in Tianjin, is close to testing its novel coronavirus vaccine in a clinical trial in China. CanSino’s approach involves taking a snippet of coronavirus’ genetic code and entwining it with a harmless virus, thereby exposing healthy volunteers to the novel infection and spurring the production of antibodies. The company said this week that Chinese authorities approved its planned trial, which will begin as soon as possible. CanSino markets a vaccine for Ebola virus in China.
Comment:
Arcturus Therapeutics
Approach: Vaccine
Stage: Preclinical
Arcturus Therapeutics is pressing forward with a vaccine that relies on engineering RNA. The company plans to take an RNA virus that has been edited to encode for proteins that will protect against infection and load it into a liquid nanoparticle. The resulting vaccine, being developed in partnership with Duke University, promises a better immune response at a lower dose than competing mRNA approaches, according to the company. The vaccine remains in preclinical development, and Arcturus has promised to start a human trial as quickly as possible.
Approach: Vaccine
Stage: Preclinical
Arcturus Therapeutics is pressing forward with a vaccine that relies on engineering RNA. The company plans to take an RNA virus that has been edited to encode for proteins that will protect against infection and load it into a liquid nanoparticle. The resulting vaccine, being developed in partnership with Duke University, promises a better immune response at a lower dose than competing mRNA approaches, according to the company. The vaccine remains in preclinical development, and Arcturus has promised to start a human trial as quickly as possible.
Comment:
BioNTech
Approach: Vaccine
Stage: Preclinical
Germany’s BioNTech is working on an mRNA vaccine for the novel coronavirus with plans to enter clinical testing in April. Like its competitors, the company uses strands of mRNA to spur the production of protective antibodies. Earlier this month, Shanghai’s Fosun Pharma signed a deal to market BioNTech’s vaccine in China if it’s eventually approved. Pfizer has agreed to co-develop the vaccine in the rest of the world.
Approach: Vaccine
Stage: Preclinical
Germany’s BioNTech is working on an mRNA vaccine for the novel coronavirus with plans to enter clinical testing in April. Like its competitors, the company uses strands of mRNA to spur the production of protective antibodies. Earlier this month, Shanghai’s Fosun Pharma signed a deal to market BioNTech’s vaccine in China if it’s eventually approved. Pfizer has agreed to co-develop the vaccine in the rest of the world.
Comment:
CureVac
Approach: Vaccine
Stage: Preclinical
Like Moderna, CureVac uses man-made mRNA to spur the production of proteins. And, like Moderna, it got a grant from the nonprofit Coalition for Epidemic Preparedness Innovations to apply its technology to coronavirus. CureVac has said it expects to have a candidate ready for animal testing by April, aiming to start a clinical study this summer. The company is also working with CEPI on a mobile mRNA manufacturing technology, one that would theoretically allow health care workers to rapidly produce vaccines to respond at the site of an outbreak.
Approach: Vaccine
Stage: Preclinical
Like Moderna, CureVac uses man-made mRNA to spur the production of proteins. And, like Moderna, it got a grant from the nonprofit Coalition for Epidemic Preparedness Innovations to apply its technology to coronavirus. CureVac has said it expects to have a candidate ready for animal testing by April, aiming to start a clinical study this summer. The company is also working with CEPI on a mobile mRNA manufacturing technology, one that would theoretically allow health care workers to rapidly produce vaccines to respond at the site of an outbreak.
Comment:
Eli Lilly
Approach: Treatment
Stage: Preclinical
Eli Lilly has partnered with a Canadian firm called AbCellera to develop antibody treatments for coronavirus infection. Using a blood sample from a coronavirus survivor, AbCellera identified more than 500 antibodies that might protect against the virus. Now it’s working with Lilly to identify which are most potent. The two companies aim to have a treatment ready for human trials within the next four months.
Approach: Treatment
Stage: Preclinical
Eli Lilly has partnered with a Canadian firm called AbCellera to develop antibody treatments for coronavirus infection. Using a blood sample from a coronavirus survivor, AbCellera identified more than 500 antibodies that might protect against the virus. Now it’s working with Lilly to identify which are most potent. The two companies aim to have a treatment ready for human trials within the next four months.
Comment:
GlaxoSmithKline
Approach: Vaccine
Stage: Preclinical
GlaxoSmithKline, one of the world’s largest vaccine manufacturers, is lending its technology to a Chinese biotech firm at work on a coronavirus vaccine. Under an agreement signed last month, GSK is providing its proprietary adjuvants — compounds that enhance the effectiveness of vaccines — to Clover Biopharmaceuticals, a privately held company based in Chengdu. Clover’s approach involves injecting proteins that spur an immune response, thereby priming the body to resist infection. The company has not said when it expects to advance into human testing. Separately, GSK is lending its scientific expertise to CEPI.
Approach: Vaccine
Stage: Preclinical
GlaxoSmithKline, one of the world’s largest vaccine manufacturers, is lending its technology to a Chinese biotech firm at work on a coronavirus vaccine. Under an agreement signed last month, GSK is providing its proprietary adjuvants — compounds that enhance the effectiveness of vaccines — to Clover Biopharmaceuticals, a privately held company based in Chengdu. Clover’s approach involves injecting proteins that spur an immune response, thereby priming the body to resist infection. The company has not said when it expects to advance into human testing. Separately, GSK is lending its scientific expertise to CEPI.
Comment:
Inovio Pharmaceuticals
Approach: Vaccine
Stage: Preclinical
Inovio has spent the last four decades working to turn DNA into medicine, and the company believes its technology could quickly generate a vaccine for the novel coronavirus. Working with CEPI grant money, Inovio has come up with a DNA vaccine it believes can generate protective antibodies and keep patients from infection. The company has partnered with a Chinese manufacturer, Beijing Advaccine Biotechnology, and is working through preclinical development with a candidate called INO-4800. The company expects to progress into clinical trials in April and has promised to manufacture 1 million doses of its candidate this year.
Approach: Vaccine
Stage: Preclinical
Inovio has spent the last four decades working to turn DNA into medicine, and the company believes its technology could quickly generate a vaccine for the novel coronavirus. Working with CEPI grant money, Inovio has come up with a DNA vaccine it believes can generate protective antibodies and keep patients from infection. The company has partnered with a Chinese manufacturer, Beijing Advaccine Biotechnology, and is working through preclinical development with a candidate called INO-4800. The company expects to progress into clinical trials in April and has promised to manufacture 1 million doses of its candidate this year.
Comment:
Johnson & Johnson
Approach: Vaccine and treatment
Stage: Preclinical
Johnson & Johnson, which has in the past responded to outbreaks of the Ebola and Zika viruses, is taking a multipronged approach to the coronavirus. The company is in the early days of developing a vaccine that would introduce patients to a deactivated version of the virus, triggering an immune response without causing infection. Human trials could begin by November. At the same time, J&J is working with the federal Biomedical Advanced Research and Development Authority on potential treatments for patients who are already infected, a process that includes investigating whether any of its older medicines might work against the coronavirus.
Approach: Vaccine and treatment
Stage: Preclinical
Johnson & Johnson, which has in the past responded to outbreaks of the Ebola and Zika viruses, is taking a multipronged approach to the coronavirus. The company is in the early days of developing a vaccine that would introduce patients to a deactivated version of the virus, triggering an immune response without causing infection. Human trials could begin by November. At the same time, J&J is working with the federal Biomedical Advanced Research and Development Authority on potential treatments for patients who are already infected, a process that includes investigating whether any of its older medicines might work against the coronavirus.
Comment:
Pfizer
Approach: Vaccine and treatment
Stage: Preclinical
Outside of its vaccine work with BioNTech, Pfizer has put out a five-point plan to address the outbreak, which includes making its technology, scientists, expertise, and manufacturing available to outside institutions. The company has also promised to create a rapid-response program to make it easier to respond to future pandemics.
Approach: Vaccine and treatment
Stage: Preclinical
Outside of its vaccine work with BioNTech, Pfizer has put out a five-point plan to address the outbreak, which includes making its technology, scientists, expertise, and manufacturing available to outside institutions. The company has also promised to create a rapid-response program to make it easier to respond to future pandemics.
Comment:
Regeneron Pharmaceuticals
Approach: Treatment
Stage: Preclinical
Regeneron has grown into a $50 billion business based on its ability to craft human antibodies out of genetically engineered mice. Now it’s tapping that technology in hopes of treating coronavirus. The company immunized its proprietary antibody-generating mice with a harmless analog of the novel coronavirus, generating potential treatments for the infection. Regeneron plans to select the two most potent antibodies and advance the cocktail into human studies by early summer. The last time Regeneron embarked on this process, during the Ebola outbreak of 2015, it came up with an antibody cocktail that roughly doubled survival rates for treated patients.
Approach: Treatment
Stage: Preclinical
Regeneron has grown into a $50 billion business based on its ability to craft human antibodies out of genetically engineered mice. Now it’s tapping that technology in hopes of treating coronavirus. The company immunized its proprietary antibody-generating mice with a harmless analog of the novel coronavirus, generating potential treatments for the infection. Regeneron plans to select the two most potent antibodies and advance the cocktail into human studies by early summer. The last time Regeneron embarked on this process, during the Ebola outbreak of 2015, it came up with an antibody cocktail that roughly doubled survival rates for treated patients.
Comment:
Sanofi
Approach: Vaccine and treatment
Stage: Preclinical
Sanofi, which has successfully developed vaccines for yellow fever and diphtheria, is working with BARDA on an answer to the coronavirus. Sanofi’s approach involves taking some of the coronavirus’s DNA and mixing it with genetic material from a harmless virus, creating a chimera that can prime the immune system without making patients sick. Sanofi expects to have a vaccine candidate to test in the lab within six months and could be ready to test a vaccine in people within a year to 18 months. Approval would likely be at least three years away, the company said. Outside of vaccines, Sanofi and Regeneron have started a clinical trial to test whether Kevzara, an approved anti-inflammatory drug, can help with the symptoms of Covid-19.
Approach: Vaccine and treatment
Stage: Preclinical
Sanofi, which has successfully developed vaccines for yellow fever and diphtheria, is working with BARDA on an answer to the coronavirus. Sanofi’s approach involves taking some of the coronavirus’s DNA and mixing it with genetic material from a harmless virus, creating a chimera that can prime the immune system without making patients sick. Sanofi expects to have a vaccine candidate to test in the lab within six months and could be ready to test a vaccine in people within a year to 18 months. Approval would likely be at least three years away, the company said. Outside of vaccines, Sanofi and Regeneron have started a clinical trial to test whether Kevzara, an approved anti-inflammatory drug, can help with the symptoms of Covid-19.
Comment:
Takeda
Approach: Treatment
Stage: Preclinical
Japanese pharma giant Takeda is at work on a treatment derived from the blood of people who have already been infected by the coronavirus. The company is drawing blood from coronavirus survivors, harvesting the plasma, and then isolating the protective antibodies that kept those patients alive. It’s not a new idea. Blood transfusions have been used to combat viral outbreaks since at least the Spanish Flu pandemic of 1918. But Takeda’s take on it could prove to be faster in development than other therapeutic approaches. According to the company, the therapy could be available to patients in 12 to 18 months.
Approach: Treatment
Stage: Preclinical
Japanese pharma giant Takeda is at work on a treatment derived from the blood of people who have already been infected by the coronavirus. The company is drawing blood from coronavirus survivors, harvesting the plasma, and then isolating the protective antibodies that kept those patients alive. It’s not a new idea. Blood transfusions have been used to combat viral outbreaks since at least the Spanish Flu pandemic of 1918. But Takeda’s take on it could prove to be faster in development than other therapeutic approaches. According to the company, the therapy could be available to patients in 12 to 18 months.
Comment:
Vir Biotechnology
Approach: Treatment
Stage: Preclinical
Vir Biotechnology, a company focused on infectious disease, has isolated antibodies from people who survived SARS, a viral relative of the novel coronavirus, and is working to determine whether they might treat the infection. Teaming up with Chinese pharma contractor WuXi Biologics, the San Francisco-based Vir is in the early stages of development and hasn’t specified when it expects to have products ready for human testing. The company has also aligned with Alnylam Pharmaceuticals to work on treatments that might halt viral replication by interfering with RNA signaling. Vir’s CEO, Biogen veteran George Scangos, is also coordinating the trade group BIO’s response to the coronavirus outbreak.
Approach: Treatment
Stage: Preclinical
Vir Biotechnology, a company focused on infectious disease, has isolated antibodies from people who survived SARS, a viral relative of the novel coronavirus, and is working to determine whether they might treat the infection. Teaming up with Chinese pharma contractor WuXi Biologics, the San Francisco-based Vir is in the early stages of development and hasn’t specified when it expects to have products ready for human testing. The company has also aligned with Alnylam Pharmaceuticals to work on treatments that might halt viral replication by interfering with RNA signaling. Vir’s CEO, Biogen veteran George Scangos, is also coordinating the trade group BIO’s response to the coronavirus outbreak.
Comment:
CHINA USING REMDESIVIR WITH SUCCESS
Wuhan Institute of Virology (China) Sought to Patent Gilead’s Remdesivir
Wuhan Institute of Virology (China) Sought to Patent Gilead’s Remdesivir
Comment:
Wuhan Institute of Virology (China) Sought to Patent Gilead’s Remdesivir
Comment:
According to a report from IPRdaily, Gilead’s Remdesivir, a new antiviral drug of nucleotide analogs’ group, was initially introduced by Gilead to fight the Ebola virus, but the results there were not successful. However, at one point The New England Journal of Medicine promulgated that Remdesivir could challenge the brand-new coronavirus, as at some point an American patient with 2019-nCoV was prescribed the drug and doctors observed after about a week conditions improved. NEJM did advocate the use of randomly controlled trials to produce more evidence.
Chinese researchers observed that Remdesivir and chloroquine, a malaria treatment, could have an impact in slowing down the coronavirus.
Chinese researchers observed that Remdesivir and chloroquine, a malaria treatment, could have an impact in slowing down the coronavirus.
Comment:
0. So it looks we have promising treatments;
Comment:
1. PARANOIA / SOCIAL DISTANCING / BATHING IN HAND SANITIZER / WUHAN AND HUBEI
Comment:
You really have to look at the areas of China that were hit by this. Basically manufacturing hubs, with slave labour, poor living and unsanitary conditions, and open animal markets, where all kinds of bats, snakes and you name it is sold daily, an has most likely lead to this aberration in nature; this virus.
Comment:
We currently have a North American population that is bathing in Clorox, drinking Hand Sanitizer, social distancing, and running the "Military Playbook for Pandemic Response" like this is a war game. The virus lives 2 to 6 hours outside a host, and needs a host to replicate, otherwise it will die. Here is the case of the disappearing SARS virus:
Comment:
Where Has SARS Gone? The Strange Case of the Disappearing Coronavirus
The emergence of Severe Acute Respiratory Syndrome (SARS) in China’s Guangdong Province in the winter of 2002 was an exemplary spillover event: it marked the passage of a lethal pathogen from nonhuman to human animals and was widely heralded as the first “plague” of the twenty-first century. The SARS coronavirus seemed to burst out of nowhere and demonstrated pandemic potential from February 2003 when it diffused globally via Hong Kong. After SARS was officially declared contained by the World Health Organization (WHO) on 5 July 2003, there were a few isolated cases but none since 2004.
somatosphere.net/201...ng-coronavirus.html/
The emergence of Severe Acute Respiratory Syndrome (SARS) in China’s Guangdong Province in the winter of 2002 was an exemplary spillover event: it marked the passage of a lethal pathogen from nonhuman to human animals and was widely heralded as the first “plague” of the twenty-first century. The SARS coronavirus seemed to burst out of nowhere and demonstrated pandemic potential from February 2003 when it diffused globally via Hong Kong. After SARS was officially declared contained by the World Health Organization (WHO) on 5 July 2003, there were a few isolated cases but none since 2004.
somatosphere.net/201...ng-coronavirus.html/
Comment:
COVID-19 TIME TO DISAPPEAR
1. Other than some limited outbreaks in the United States and Canada, I have not seen a level of fear in Society, and in the Markets.... EVER;
2. This is clearly the point of MAX HYSTERIA. The stories have started to taper off as of March 18, 2020, and we feel there is a high probability of a bottom here, or something close to it;
3. If your time horizon is 12+ months out, you should be buying here, at these levels, in your favourites names, strong companies positioned for many key things going forward;
1. Other than some limited outbreaks in the United States and Canada, I have not seen a level of fear in Society, and in the Markets.... EVER;
2. This is clearly the point of MAX HYSTERIA. The stories have started to taper off as of March 18, 2020, and we feel there is a high probability of a bottom here, or something close to it;
3. If your time horizon is 12+ months out, you should be buying here, at these levels, in your favourites names, strong companies positioned for many key things going forward;
Comment:
4. We know that the Stock Market is forward looking, and it can smell an OVER-HYPED NON-EVENT AND UNWARRANTED SELLOFF BEFORE ANYBODY.
Comment:
5. We believe the VIOLENT trading range of last week may have signaled a bottom, or a final bottoming process in equities.
Comment:
SOCIAL DISTANCING / HOME DEPOT MADNESS / TRIBUTE TO CRAMER / ON THE GROUND CLUES TO THE FUTURE
Comment:
1. HOME DEPOT
I was in Home Depot yesterday, in Toronto, a "small outbreak center", and a place where you can't buy hand sanitizer, toilet paper, or canned goods right now, without a gun. Actually somebody pulled a gun at Loblaws a couple of days ago over sundry items!
So I walk in and all staff are wearing gloves, marked, and armed with "hand sanitizer on a rope".
There are Security Guards at the entrance, with Hand Sanitizer and reassuring advise about going inside.
They are mopping the FLOOR continuously with a CLOROX and the store simply smells like BLEACH and cleaning solution from END to END.
The counter where you check out is sprayed with LYSOL as you come to the counter, and as soon as you leave.
STORE STAFF IS MAKING SURE PEOPLE ARE STANDING APART FROM EACH OTHER AND NOT CROWDING.
I was in Home Depot yesterday, in Toronto, a "small outbreak center", and a place where you can't buy hand sanitizer, toilet paper, or canned goods right now, without a gun. Actually somebody pulled a gun at Loblaws a couple of days ago over sundry items!
So I walk in and all staff are wearing gloves, marked, and armed with "hand sanitizer on a rope".
There are Security Guards at the entrance, with Hand Sanitizer and reassuring advise about going inside.
They are mopping the FLOOR continuously with a CLOROX and the store simply smells like BLEACH and cleaning solution from END to END.
The counter where you check out is sprayed with LYSOL as you come to the counter, and as soon as you leave.
STORE STAFF IS MAKING SURE PEOPLE ARE STANDING APART FROM EACH OTHER AND NOT CROWDING.
Comment:
STORES THAT ARE OPEN / BUT YOU CAN'T REALLY GO IT
1. So a lot of stores locally are STILL OPEN, but they are there with CURBSIDE pickup and you basically can come at get your items, they open the door, fire them onto the street and away you go.
1. So a lot of stores locally are STILL OPEN, but they are there with CURBSIDE pickup and you basically can come at get your items, they open the door, fire them onto the street and away you go.
Comment:
UNITED STATES AND CANADA AND NOT A HELL HOLE like HUBEI PROVINCE
2. So things continue to function, and you have to think about what you are talking about here:
But the NIH study found that the SARS-CoV-2 virus survives for longer on cardboard – up to 24 hours – and up to 2-3 days on plastic and stainless-steel surfaces. (Learn how to clean your mobile phone properly.)
But there is a speedier option: research has shown that coronaviruses can be inactivated within a minute by disinfecting surfaces with 62-71% alcohol, or 0.5% hydrogen peroxide bleach or household bleach containing 0.1% sodium hypochlorite. Higher temperatures and humidity also tend to result in other coronaviruses dying quicker, although research has shown that a related coronavirus that causes Sars could be killed by temperatures above 56°C or 132°F (hotter than even a bath scalding enough to cause injury) at a rate of about 10,000 viral particles every 15 minutes.
www.bbc.com/future/a...rus-last-on-surfaces
2. So things continue to function, and you have to think about what you are talking about here:
But the NIH study found that the SARS-CoV-2 virus survives for longer on cardboard – up to 24 hours – and up to 2-3 days on plastic and stainless-steel surfaces. (Learn how to clean your mobile phone properly.)
But there is a speedier option: research has shown that coronaviruses can be inactivated within a minute by disinfecting surfaces with 62-71% alcohol, or 0.5% hydrogen peroxide bleach or household bleach containing 0.1% sodium hypochlorite. Higher temperatures and humidity also tend to result in other coronaviruses dying quicker, although research has shown that a related coronavirus that causes Sars could be killed by temperatures above 56°C or 132°F (hotter than even a bath scalding enough to cause injury) at a rate of about 10,000 viral particles every 15 minutes.
www.bbc.com/future/a...rus-last-on-surfaces
Comment:
"But there is a speedier option: research has shown that coronaviruses can be inactivated within a minute by disinfecting surfaces with 62-71% alcohol, or 0.5% hydrogen peroxide bleach or household bleach containing 0.1% sodium hypochlorite. Higher temperatures and humidity also tend to result in other coronaviruses dying quicker, although research has shown that a related coronavirus that causes Sars could be killed by temperatures above 56°C or 132°F (hotter than even a bath scalding enough to cause injury) at a rate of about 10,000 viral particles every 15 minutes."
Comment:
"But there is a speedier option: research has shown that coronaviruses can be inactivated within a minute by disinfecting surfaces with 62-71% alcohol, or 0.5% hydrogen peroxide bleach or household bleach containing 0.1% sodium hypochlorite. Higher temperatures and humidity also tend to result in other coronaviruses dying quicker, although research has shown that a related coronavirus that causes Sars could be killed by temperatures above 56°C or 132°F (hotter than even a bath scalding enough to cause injury) at a rate of about 10,000 viral particles every 15 minutes."
Comment:
We posted this twice, so you don't have any misconceptions about what is happening in NORTH AMERICA RIGHT NOW. A PANIC OF ALCOHOL RELATED PROBLEMS AND BLEACH BEING SPREAD AROUND THE COUNTRY LIKE IT WAS BEER AT A HILLBILLY FESTIVAL!
Comment:
So I am not sure how THIS COVID-19 VIRUS CAN POSSIBLE SURVIVE IN A CONTINENT OF COMPLETE PARANOIA WHERE WE ARE DRINKING THE HAND SANITIZER / CLOROX / LYSOL COMBO FOR BREAKFAST LUNCH AND DINNER!
Comment:
FART IN THE WIND / We are placing our BET on the People of Canada and the United States. Your fear, and irrationality will SAVE US ALL!
So When SARS 2.0 disappears like a fart in wind in the next few weeks, you heard it here first.
If we are WRONG and it is the end of the world, doesn't it really matter? We will either be rich buying at these levels, or DEAD, so this is a no lose situation!
WHERE HAS SARS GONE, THE STRANGE CASE OF THE DISAPPEARING CORONA VIRUS
bioethics.georgetown...s-by-robert-peckham/
So When SARS 2.0 disappears like a fart in wind in the next few weeks, you heard it here first.
If we are WRONG and it is the end of the world, doesn't it really matter? We will either be rich buying at these levels, or DEAD, so this is a no lose situation!
WHERE HAS SARS GONE, THE STRANGE CASE OF THE DISAPPEARING CORONA VIRUS
bioethics.georgetown...s-by-robert-peckham/
Comment:
AMD OPEN PRICE
$42.55
$42.55
Comment:
- drchelsea
- The AMD Whisperer
- The AMD Whisperer
Comment:
GOLD COMMENT
We apologized for our GLD call at $140, but with it at $142.50 in the pre-market today, it appears we predicted it yet again.
We apologized for our GLD call at $140, but with it at $142.50 in the pre-market today, it appears we predicted it yet again.
Comment:
FEBRUARY 21 CRASH / OPTIONS EXPIRATION / MARCH 20 REVERSAL / SAME AS 1987 ALL OVER AGAIN (MECHANICALLY)
NOTES TO FOLLOW!
NOTES TO FOLLOW!
Comment:
FEBRUARY 21ST CRASH / SAME AS 1987 OPTIONS INSURANCE / SHORT AND LONG GAMMA
A Computer Lesson Still Unlearned
This was an ALGORITHM CRASH.
It was just a quarter-century ago that Wall Street was shaken to its core by the Oct. 19, 1987, stock market crash.
On one day, the Dow Jones industrial average lost 23 percent of its value. People wondered if that heralded a new Depression. A front page headline in The New York Times asked, “Does 1987 Equal 1929?”
It did not. The next recession, a mild one, was more than two years away.
What it did signify was the beginning of the destruction of markets by dumb computers. Or, to be fair to the computers, by computers programmed by fallible people and trusted by people who did not understand the computer programs’ limitations. As computers came in, human judgment went out.
That process, then in its infancy, gained speed over the next two decades. By 2008, it really did threaten a new Depression. But we’ll get to that later.
Advertisement
Continue reading the main story
The 1987 villain was something called portfolio insurance. It was a product that used stock index futures and options to assure institutional investors that they need not worry if market prices seemed to be unreasonably high.
Portfolio insurance would let them get out with minimal damage if markets ever began to fall. They would simply sell ever-increasing numbers of futures contracts, a process known as dynamic hedging.
www.nytimes.com/2012...-by-wall-street.html
A Computer Lesson Still Unlearned
This was an ALGORITHM CRASH.
It was just a quarter-century ago that Wall Street was shaken to its core by the Oct. 19, 1987, stock market crash.
On one day, the Dow Jones industrial average lost 23 percent of its value. People wondered if that heralded a new Depression. A front page headline in The New York Times asked, “Does 1987 Equal 1929?”
It did not. The next recession, a mild one, was more than two years away.
What it did signify was the beginning of the destruction of markets by dumb computers. Or, to be fair to the computers, by computers programmed by fallible people and trusted by people who did not understand the computer programs’ limitations. As computers came in, human judgment went out.
That process, then in its infancy, gained speed over the next two decades. By 2008, it really did threaten a new Depression. But we’ll get to that later.
Advertisement
Continue reading the main story
The 1987 villain was something called portfolio insurance. It was a product that used stock index futures and options to assure institutional investors that they need not worry if market prices seemed to be unreasonably high.
Portfolio insurance would let them get out with minimal damage if markets ever began to fall. They would simply sell ever-increasing numbers of futures contracts, a process known as dynamic hedging.
www.nytimes.com/2012...-by-wall-street.html
Comment:
This whole debacle for whatever reason:
1. Overvalued Market;
2. Irrational Exuberance;
3. It was a Bear Market Rally;
4. Black Swan x 2 (Oil + Virus);
5. Trump / Trump / Trump;
6. Random and Inevitable and Impossible to Predict;
7. Dealer Hedging and Long / Short Gamma;
8. Add X Here;
1. Overvalued Market;
2. Irrational Exuberance;
3. It was a Bear Market Rally;
4. Black Swan x 2 (Oil + Virus);
5. Trump / Trump / Trump;
6. Random and Inevitable and Impossible to Predict;
7. Dealer Hedging and Long / Short Gamma;
8. Add X Here;
Comment:
This whole thing started on the ROLL-OVER on February 21 of the dealer positioning from Long to Short Gamma. If memory serves we were well above the 3100 positioning that Charlie from Nomura (invented vix) outlined as the flip position:
Comment:
Nomura Warns Of Imminent "Gamma-Flip" Risk In Stocks
While the last few weeks have seen endless headlines that "a trade deal is close" which, thanks to headline-scanning algos has ignited an endless short-squeeze to lift stocks to record highs, the last two days have seen a very sudden and very dramatic plunge in stocks on the heels of some less-than-positive trade-deal comments.
This has plunged the market's odds of a deal notably...
www.zerohedge.com/ma...mma-flip-risk-stocks
While the last few weeks have seen endless headlines that "a trade deal is close" which, thanks to headline-scanning algos has ignited an endless short-squeeze to lift stocks to record highs, the last two days have seen a very sudden and very dramatic plunge in stocks on the heels of some less-than-positive trade-deal comments.
This has plunged the market's odds of a deal notably...
www.zerohedge.com/ma...mma-flip-risk-stocks
Comment:
THE GAMMA PIN
So the long dealer position in the Gamma Pin above 3100 back in October of 2019 is what took up PERPETUALLY (ALMOST)
So the long dealer position in the Gamma Pin above 3100 back in October of 2019 is what took up PERPETUALLY (ALMOST)
Comment:
Comment:
HEISENBERG FROM SEEKING ALPHA
This guy if sums it up really well, and this is exactly what happened:
What The Hell Is Going On?
Mar. 11, 2020 3:03 PM ET|
1095 comments
|
Includes: QQQ, SPY
The Heisenberg
The Heisenberg
Currencies, macro, commodities, geopolitics
The Heisenberg Report
(27,862 followers)
Summary
The Dow fell into a bear market (at least intraday) on Wednesday, another session that found the benchmark down more than a 1,000 points.
This "yo-yo" price action is not as inexplicable as it seems, and regular readers are acutely aware of the dynamics that are exacerbating things.
And yet, considering the circumstances (which are, in a word, extraordinary), I wanted to pen another "guide for the perplexed."
seekingalpha.com/art...hat-hell-is-going-on
This guy if sums it up really well, and this is exactly what happened:
What The Hell Is Going On?
Mar. 11, 2020 3:03 PM ET|
1095 comments
|
Includes: QQQ, SPY
The Heisenberg
The Heisenberg
Currencies, macro, commodities, geopolitics
The Heisenberg Report
(27,862 followers)
Summary
The Dow fell into a bear market (at least intraday) on Wednesday, another session that found the benchmark down more than a 1,000 points.
This "yo-yo" price action is not as inexplicable as it seems, and regular readers are acutely aware of the dynamics that are exacerbating things.
And yet, considering the circumstances (which are, in a word, extraordinary), I wanted to pen another "guide for the perplexed."
seekingalpha.com/art...hat-hell-is-going-on
Comment:
If you are not signed up for Seeking Alpha you should be:
They gave us a CLUE ON FEBRUARY 14TH, that the Market was about to implode, let me look for it here...
They gave us a CLUE ON FEBRUARY 14TH, that the Market was about to implode, let me look for it here...
Comment:
Comment:
On February 14th, Seeking Alpha published a story which our parsing and sentiment engine picked up (it is locked now if you don't subscribe), but what is said was SOMEBODY, probably and institution COLLARED, or basically protected a 110 Million Position in AMD, and did it at $55 on February 14th:
seekingalpha.com/art...-rally-may-be-to-end
seekingalpha.com/art...-rally-may-be-to-end
Comment:
A Week Later, the Market CRASHED.
Comment:
FEBRUARY 14 TO 21 2020
Interesting thoughts. We also saw a bunch of signs and clues in February 14th to 20th timeframe, and said that something was up, something was brewing underneath the Market.
Interesting thoughts. We also saw a bunch of signs and clues in February 14th to 20th timeframe, and said that something was up, something was brewing underneath the Market.
Comment:
We published a story at $57.75 about protecting capital and hedging your Market and AMD position, but we had NO IDEA it was going down 40%, WE hedged for 20%. Just like Ray Dalio. We such is life. So hopefully grabbing a real tradable bottom here will take us all back to riches, especially those like us that only lost about 5 percent in the CRASH, and made tons on the tradable bounces on the way down. We also profited from shorting Gold, and our Hedge in UVXY and other volatility plays, as well as the AMD $55 puts that we told everyone to buy in mid February, which we dumped at $45 (as little too soon, but we are optimistic on AMD and we don't like to hold PUTS against such a great STOCK).
Comment:
LIMIT UP
So we are limit up and we predicted this yesterday.
We are the Prediction Company:
en.wikipedia.org/wik...i/Prediction_Company
So we are limit up and we predicted this yesterday.
We are the Prediction Company:
en.wikipedia.org/wik...i/Prediction_Company
Comment:
AMD PRICE TARGET CUT AT WELLS FARGO FROM $55 TO $50
Wells Fargo cuts price targets in IT Hardware & Communications Networking space
Wells Fargo analyst Aaron Rakers said it is impossible to know what the fundamental impact of COVID-19 will be across his coverage universe in the IT Hardware & Communications Networking space, and that while he thinks it is very important to consider that many companies are materially different today than they were during the 2008-2009 financial crisis, most of his discussions are pointing to the fundamental deterioration of this timeframe as a guide post. The analyst says Nvidia (NVDA) remains his top pick, as he remains positive on its data center growth story, and believes Micron's (MU) negative free cash flow generation could be short-lived. Rakers thinks Western Digital (WDC) has fallen too far as checks point to ongoing positive hyperscale demand. The analyst lowered his price target for Nvidia to $280 from $320, for Intel (INTC) to $56 from $70, for AMD (AMD) to $50 from $55, for Xilinx (XLNX) to $80 from $95, for Micron to $50 from $70, for Western Digital to $60 from $85, for Seagate to $50 from $52 and for Arrow Electronics (ARW) to $48 from $72.
Wells Fargo cuts price targets in IT Hardware & Communications Networking space
Wells Fargo analyst Aaron Rakers said it is impossible to know what the fundamental impact of COVID-19 will be across his coverage universe in the IT Hardware & Communications Networking space, and that while he thinks it is very important to consider that many companies are materially different today than they were during the 2008-2009 financial crisis, most of his discussions are pointing to the fundamental deterioration of this timeframe as a guide post. The analyst says Nvidia (NVDA) remains his top pick, as he remains positive on its data center growth story, and believes Micron's (MU) negative free cash flow generation could be short-lived. Rakers thinks Western Digital (WDC) has fallen too far as checks point to ongoing positive hyperscale demand. The analyst lowered his price target for Nvidia to $280 from $320, for Intel (INTC) to $56 from $70, for AMD (AMD) to $50 from $55, for Xilinx (XLNX) to $80 from $95, for Micron to $50 from $70, for Western Digital to $60 from $85, for Seagate to $50 from $52 and for Arrow Electronics (ARW) to $48 from $72.
5. We noticed a strong trading range for various stocks like AMD, MSFT, and many others, suggesting a final bottoming process and floor to the Market;